854
Views
4
CrossRef citations to date
0
Altmetric
Brief Report

Inhibition studies with simple and complex (in)organic anions of the γ-carbonic anhydrase from Mammaliicoccus (Staphylococcus) sciuri, MscCAγ

, ORCID Icon, ORCID Icon & ORCID Icon
Article: 2173748 | Received 28 Dec 2022, Accepted 23 Jan 2023, Published online: 31 Jan 2023

Abstract

The γ-carbonic anhydrase (CA, EC 4.2.1.1) from the pathogenic bacterium, Mammaliicoccus (Staphylococcus) sciuri (MscCAγ) was recently cloned and purified by our groups. Here we investigated inhibition of this enzyme with (in)organic simple and complex anions, in the search of inhibitors with potential applications. The most effective inhibitors (KIs in the micromolar range) were peroxydisulfate and trithiocarbonate, whereas submillimolar inhibition was observed with N,N-diethyldithiocarbamate and phenylboronic acid (KIs of 0.5–0.9 mM). Thiocyanate, hydrogensulfide, bisulphite, stannate, divanadate, tetraborate, perrhenate, perruthenate, hexafluorophosphate, triflate and iminodisulfonate showed KIs of 1.0–13.7 mM. Cyanate, cyanide, azide, carbonate, nitrate, tellurate, selenocyanide, tetrafluoroborate, sulfamide, sulphamic acid and phenylarsonic acid were weaker inhibitors, with KIs in the range of 25.2–95.5 mM, whereas halides, bicarbonate, nitrite, sulphate, perchlorate and fluorosulfonate did not show inhibitory action up until 100 mM concentrations in the assay system. Finding more effective MscCAγ inhibitors may be helpful to fight drug resistance to antibiotics.

Introduction

Carbonic anhydrases (CAs, EC 4.2.1.1) are present in prokaryotes and eukaryotes, with a large number of genetic families encoding themCitation1–4. By efficiently catalysing the hydration of CO2 to bicarbonate and protons, these enzymes participate in many crucial physiologic processes, such as pH regulationCitation1–4, metabolism (as they are involved in several biosynthetic pathways)Citation5, photosynthesis (in plants and cyanobacteria)Citation6, electrolyte secretion (in vertebrates)Citation7, respiration and CO2/bicarbonate homeostasisCitation8, just to mention the essential ones. Bacteria encode for at least 4 CA classes (α-, β-, γ- and ι-CAs)Citation2,Citation4 and in many pathogenic ones (but also in fungi or protozoans) the CAs are also involved in virulence, acclimation in specific tissues/organs and pathogen survival/fitness in environments possessing highly variable pH, bicarbonate and CO2 levelsCitation2,Citation9. Thus, recently, inhibition of bacterial CAs started to be considered as a valid approach for obtaining antibiotics with a novel mechanism of actionCitation2,Citation10,Citation11, and at least for Helicobacter pyloriCitation12, Neisseria gonorrhoeaeCitation11,Citation13 and vancomycin-resistant EnterococciCitation14, detailed in vitro, in vivo and animal model proof-of-principle studies provided the experimental evidence that the approach is feasible and provides a powerful antibacterial effectCitation2,Citation10–14. Up until now, most such studies have been performed with sulphonamide CA inhibitors (CAIs) targeting these bacterial enzymesCitation10–14. There are, however, many other less investigated chemotypes, such as the (in)organic anions, many of which act as zinc binders, as well as compounds possessing different inhibition mechanisms (e.g. anchoring to the zinc-coordinated water, occlusion of the active site entrance or out of the active site binding) which should be taken into considerationCitation15. Apart natural products, which offer interesting structures for designing structurally novel enzyme inhibitors, including CAIsCitation16, the investigation of simple (in)organic anions (or similar small molecules) afforded the discovery of new CAI classes, such as mono- and dithiocarbamatesCitation15, selenolsCitation17, ninhydrinsCitation18 and many other chemotypesCitation15. Many such new types of reported CAIs were among the derivatives showing relevant CA isoform-selective inhibition profilesCitation15.

Recently, we reportedCitation19 the cloning, purification and initial characterisation of a γ-class CA from the Gram-positive bacterium Mammaliicoccus sciuri (previously known as Staphylococcus sciuri), MscCAγ, which is responsible of infections in humans and various other wild/domestic animals, but also of gene transfer phenomena to other bacteria, that confer drug resistance to multiple antibioticsCitation19. We hypothesisedCitation19 that inhibition of this enzyme may lead to a novel strategy for limiting the spread of multidrug resistance and investigated a range of sulphonamides and sulfamates as MscCAγ inhibitors. Some sulphonamides were indeed rather effective inhibitors, but compounds with an optimal selectivity profile for inhibiting the bacterial over the human enzymes have not yet been detected so far. Thus, here we report the investigation of (in)organic anions and structurally related small molecules as MscCAγ inhibitors, in the search of compounds with interesting inhibition profiles.

Materials and methods

Reagents

Anions and small molecules were commercially available reagents of the highest available purity from Sigma-Aldrich (Milan, Italy). The purity of tested compounds was higher than 99%.

CA activity and inhibition measurements

An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO2 hydration activityCitation20. Phenol red at a concentration of 0.2 mM was used as pH indicator, working at the absorbance maximum of 557 nm, with 10 mM TRIS (pH 8.3) as buffer, and in the presence of 10 mM NaClO4 for maintaining constant the ionic strength, following the initial rates of the CA-catalysed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10–50 mM) were prepared in distilled-deionized water and dilutions up to 0.01 µM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the enzyme-inhibitor complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, whereas the kinetic parameters for the uninhibited enzymes from Lineweaver-Burk plots, as reported earlierCitation21–23, and represent the mean from at least three different determinations. MscCAγ was obtained as reported earlierCitation19 and its concentration in the assay system was of 12.6 nM.

Discussion and conclusions

Anions, both inorganic and organic ones, represent a relevant class of CAIs, which in most cases act as zinc bindersCitation15. They coordinate to the metal ion from the enzyme active site, frequently as monodentate ligands, with the preservation of the tetrahedral geometry of the active site metal ion, although rarely, an addition to the coordination sphere was observed, which led to trigonal bipyramidal geometries (at least for the zinc ion present in many classes of CAsCitation1,Citation15) Thus, we included in our study a large number of inorganic and organic anions, as well as small molecules structurally related to them (), known to interact with metal ions from metalloenzyme active sitesCitation1,Citation2,Citation15.

Table 1. Inhibition of human isoform hCA II and the bacterial enzyme from Mammaliicoccus sciuri (MscCAγ) with (in)organic anions and small molecules, by a CO2 hydrase, stopped-flow assayCitation20.

Data of , in which MscCAγ and hCA II (the human isoform II) anion inhibition data are presented, show the following inhibition profile of the new enzyme investigated here (human enzyme data are presented for comparison reasons):

  1. The following anions did not inhibit MscCAγ up to 100 mM concentration in the assay system: all halides, bicarbonate, nitrite, sulphate, perchlorate and fluorosulfonate. The last anion is a potent hCA II inhibitor () whereas the remaining ones also poorly inhibit the human isoform (apart iodide which is a medium potency hCA II inhibitor).

  2. Weak inhibition of MscCAγ has been observed with cyanate, cyanide, azide, carbonate, nitrate, tellurate, selenocyanide, tetrafluoroborate, sulfamide, sulphamic acid and phenylarsonic acid, which presented KIs in the range of 25.2–95.5 mM. Some of these anions/compounds (e.g. nitrate, tellurate, tetrafluoroborate) are known to possess low affinity to complexate metal ions in solution or within enzymes active sitesCitation24. However, cyanate, cyanide, azide, and other anions have a very high affinity for cationsCitation24, and it is thus surprising that so diverse anions possess similar inhibition constants for MscCAγ. The same should be mentioned on sulfamide and sulfanic acid (sulfamate), which effectively inhibit α-CAs (including hCA II, as shown in )Citation25, whereas their activity on MscCAγ is quite weak.

  3. Effective MscCAγ inhibitory activity has been registered for thiocyanate, hydrogensulfide, bisulphite, stannate, divanadate, tetraborate, perrhenate, perruthenate, hexafluorophosphate, triflate and iminodisulfonate, which showed KIs in the range of 1.0–13.7 mM. Again, some of these anions (thiocyanate, hydrogensulfide) are very good metal complexing agents, whereas others (haxafluorophosphate, triflate, etc.) are well-known for their low affinity for metal ionsCitation25. Thus, it is difficult to rationalise these results, considering the fact that such effects have been described for other CAs earlier (e.g. for hCA II)Citation15,Citation25.

  4. Submillimolar MscCAγ inhibitory activity has been evidenced for selenite, pyrophosphate, N,N-diethyldithiocarbamate and phenylboronic acid (KIs in the range of 0.5–0.9 mM), whereas peroxydisulfate and trithiocarbonate were the most effective inhibitors, with inhibition constants of 60 and 70 µM, respectively.

  5. The inhibition profiles with (in)organic anions of the bacterial and human CAs investigated are very different, which signifies that it might be possible to design inhibitors selective for the pathogenic enzyme, as already demonstrated for other bacterial CAsCitation2,Citation10–12.

In conclusion, we report here the first inhibition study with (in)organic anions and small molecules (sulfamide, sulphamic acid, phenylboronic acid and phenylarsonic acid) of MscCAγ. The most effective inhibitors (KIs in the micromolar range) were peroxydisulfate and trithiocarbonate, whereas submillimolar inhibition was observed with N,N-diethyldithiocarbamate and phenylboronic acid (KIs of 0.5–0.9 mM). Thiocyanate, hydrogensulfide, bisulphite, stannate, divanadate, tetraborate, perrhenate, perruthenate, hexafluorophosphate, triflate and iminodisulfonate showed KIs of 1.0–13.7 mM. Cyanate, cyanide, azide, carbonate, nitrate, tellurate, selenocyanide, tetrafluoroborate, sulfamide, sulphamic acid and phenylarsonic acid were weaker inhibitors, with KIs in the range of 25.2–95.5 mM, whereas halides, bicarbonate, nitrite, sulphate, perchlorate and fluorosulfonate did not show inhibitory action up until 100 mM concentrations in the assay system. Although we did not find highly effective MscCAγ inhibitors among the small molecules and anions investigated here, some of the tested compounds, such as N,N-diethyldithiocarbamate, phenylboronic acid or trithiocarbonate, which showed relevant inhibition, may be developed and used as leads for the design of presumably more effective bacterial CA inhibitors.

Disclosure statement

No potential competing interest was reported by all authors except CTS. CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

The Italian Ministry for University and Research (MIUR) is thanked for the grant FISR2019_04819 BacCAD (to CC and CTS).

References

  • (a) Aspatwar A, Tolvanen MEE, Barker H, Syrjänen L, Valanne S, Purmonen S, Waheed A, Sly WS, Parkkila S. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. Physiol Rev. 2022;102(3):1327–1383. (b) Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov. 2008;7:168–181. (c) Aspatwar A, Supuran CT, Waheed A, Sly WS, Parkkila S. Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease. J Physiol. 2022;601(2):257–274.
  • (a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30(2):325–332. (b) Flaherty DP, Seleem MN, Supuran CT. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem. 2021;13(19):1619–1622. (c) De Luca V, Carginale V, Supuran CT, Capasso C. The gram-negative bacterium Escherichia coli as a model for testing the effect of carbonic anhydrase inhibition on bacterial growth. J Enzyme Inhib Med Chem. 2022;37:2092–2098. (d) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets. 2015; 19:1689–1704. (e) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;28(10):745–754. (f) Nocentini A, Capasso C, Supuran CT. Carbonic anhydrase inhibitors as Novel antibacterials in the era of antibiotic resistance: Where are we now? Antibiotics. 2023;12(1):142.
  • (a) Angeli A, Urbański LJ, Capasso C, Parkkila S, Supuran CT. Activation studies with amino acids and amines of a β-carbonic anhydrase from Mammaliicoccus (Staphylococcus) sciuri previously annotated as Staphylococcus aureus (SauBCA) carbonic anhydrase. J Enzyme Inhib Med Chem. 2022;37(1):2786–2792. (b) Da’dara AA, Angeli A, Ferraroni M, Supuran CT, Skelly PJ. Crystal structure and chemical inhibition of essential schistosome host-interactive virulence factor carbonic anhydrase SmCA. Commun Biol. 2019;2:333. (c) Vullo D, Del Prete S, Fisher GM, Andrews KT, Poulsen SA, Capasso C, Supuran CT. Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorg Med Chem. 2015;23(3):526–531. (d) Nocentini A, Supuran CT, Capasso C. An overview on the recently discovered iota-carbonic anhydrases. J Enzyme Inhib Med Chem. 2021;36(1):1988–1995. (e) Hewitson KS, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT. Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. J Med Chem. 2012;55(7):3513–3520. (f) Supuran CT, Capasso C. A highlight on the inhibition of fungal carbonic anhydrases as drug targets for the antifungal armamentarium. Int J Mol Sci. 2021; 22(9):4324.
  • (a) Hirakawa Y, Hanawa Y, Yoneda K, Suzuki I. Evolution of a chimeric mitochondrial carbonic anhydrase through gene fusion in a haptophyte alga. FEBS Lett. 2022;596(23):3051–3059. (b) Hirakawa Y, Senda M, Fukuda K, Yu HY, Ishida M, Taira M, Kinbara K, Senda T. Characterization of a novel type of carbonic anhydrase that acts without metal cofactors. BMC Biol. 2021;19(1):105. (c) Pierella Karlusich JJ, Bowler C, Biswas H. Carbon dioxide concentration mechanisms in natural populations of marine diatoms: insights from tara oceans. Front Plant Sci. 2021;12:657821. (d) Jensen EL, Clement R, Kosta A, Maberly SC, Gontero B. A new widespread subclass of carbonic anhydrase in marine phytoplankton. Isme J. 2019;13(8):2094–2106.
  • (a) Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8(2):25. (b) Angeli A, Carta F, Nocentini A, Winum JY, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, Simone G, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10(10):412. (c) Supuran CT. Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. J Enzyme Inhib Med Chem. 2022;37(1):2478–2488.
  • (a) Flamholz AI, Dugan E, Panich J, Desmarais JJ, Oltrogge LM, Fischer WW, Singer SW, Savage DF. Trajectories for the evolution of bacterial CO2-concentrating mechanisms. Proc Natl Acad Sci USA. 2022;119(49):e2210539119. (b) Langella E, Di Fiore A, Alterio V, Monti SM, De Simone G, D’Ambrosio K. α-CAs from photosynthetic organisms. Int J Mol Sci. 2022;23(19):12045. (c) Crawford JD, Cousins AB. Limitation of C4 photosynthesis by low carbonic anhydrase activity increases with temperature but does not influence mesophyll CO2 conductance. J Exp Bot. 2022;73(3):927–938.
  • (a) Giacomin M, Drummond JM, Supuran CT, Goss GG. The roles of plasma accessible and cytosolic carbonic anhydrases in bicarbonate (HCO3–) excretion in Pacific hagfish (Eptatretus stoutii). J Comp Physiol B. 2022;192(6):713–725. (b) Zhou Z, Qian J, Kini A, Riederer B, Römermann D, Gros G, Seidler U. Loss of luminal carbonic anhydrase XIV results in decreased biliary bicarbonate output, liver fibrosis, and cholangiocyte proliferation in mice. Pflugers Arch. 2022;474(5):529–539. (c) Deniz S, Uysal TK, Capasso C, Supuran CT, Ozensoy Guler O. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection? J Enzyme Inhib Med Chem. 2021;36(1):1230–1235.
  • (a) Bejaoui M, Pantazi E, De Luca V, Panisello A, Folch-Puy E, Hotter G, Capasso C, Supuran CT, Roselló-Catafau J. Carbonic anhydrase protects fatty liver grafts against ischemic reperfusion damage. PLoS One. 2015;10(7):e0134499. (b) Lee D, Hong JH. The fundamental role of bicarbonate transporters and associated carbonic anhydrase enzymes in maintaining ion and pH homeostasis in non-secretory organs. Int J Mol Sci. 2020;21(1):339. (c) Bernardino RL, Dias TR, Moreira BP, Cunha M, Barros A, Oliveira E, Sousa M, Alves MG, Oliveira PF. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. Febs J. 2019;286(7):1393–1406.
  • (a) Campestre C, De Luca V, Carradori S, Grande R, Carginale V, Scaloni A, Supuran CT, Capasso C. Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol. 2021;12:629163. (b) Kim S, Yeon J, Sung J, Kim NJ, Hong S, Jin MS. Structural insights into novel mechanisms of inhibition of the major β-carbonic anhydrase CafB from the pathogenic fungus Aspergillus fumigatus. J Struct Biol. 2021;213(1):107700. (c) Bonardi A, Nocentini A, Osman SM, Alasmary FA, Almutairi TM, Abdullah DS, Gratteri P, Supuran CT. Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study. J Enzyme Inhib Med Chem. 2021;36(1):469–479. (d) Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov. 2020;15(2):145–158. e) Beatriz Vermelho A, Rodrigues GC, Nocentini A, Mansoldo FRP, Supuran CT. Discovery of novel drugs for Chagas disease: is carbonic anhydrase a target for antiprotozoal drugs? Expert Opin Drug Discov. 2022;17(10):1147–1158.
  • (a) An W, Holly KJ, Nocentini A, Imhoff RD, Hewitt CS, Abutaleb NS, Cao X, Seleem MN, Supuran CT, Flaherty DP. Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):1838–1844. (b) Giovannuzzi S, Hewitt CS, Nocentini A, Capasso C, Costantino G, Flaherty DP, Supuran CT. Inhibition studies of bacterial α-carbonic anhydrases with phenols. J Enzyme Inhib Med Chem. 2022;37(1):666–671. (c) Giovannuzzi S, Hewitt CS, Nocentini A, Capasso C, Flaherty DP, Supuran CT. Coumarins effectively inhibit bacterial α-carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):333–338. (d) Abutaleb NS, Elhassanny AEM, Nocentini A, Hewitt CS, Elkashif A, Cooper BR, Supuran CT, Seleem MN, Flaherty DP. Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2022;37(1):51–61.
  • (a) Giovannuzzi S, Abutaleb NS, Hewitt CS, Carta F, Nocentini A, Seleem MN, Flaherty DP, Supuran CT. Dithiocarbamates effectively inhibit the α-carbonic anhydrase from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2022;37(1):1–8. (b) Nocentini A, Hewitt CS, Mastrolorenzo MD, Flaherty DP, Supuran CT. Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2021;36(1):1061–1066. (c) Hewitt CS, Abutaleb NS, Elhassanny AEM, Nocentini A, Cao X, Amos DP, Youse MS, Holly KJ, Marapaka AK, An W, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021;7(7):1969–1984. (d) Kumar Marapaka A, Nocentini A, Youse MS, An W, Holly KJ, Das C, Yadav R, Seleem MN, Supuran CT, Flaherty DP. Structural characterization of thiadiazolesulfonamide inhibitors bound to Neisseria gonorrhoeae α‑carbonic anhydrase. ACS Med Chem Lett. 2022;14(1):103–109.
  • (a) Rahman MM, Tikhomirova A, Modak JK, Hutton ML, Supuran CT, Roujeinikova A. Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathog. 2020;12:20. (b) Modak JK, Tikhomirova A, Gorrell RJ, Rahman MM, Kotsanas D, Korman TM, Garcia-Bustos J, Kwok T, Ferrero RL, Supuran CT, et al. Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem. 2019;34(1):1660–1667. (c) Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem. 2016;59(24):11098–11109. (d) Modak JK, Liu YC, Machuca MA, Supuran CT, Roujeinikova A. Structural basis for the inhibition of Helicobacter pylori α-carbonic anhydrase by sulfonamides. PLoS One. 2015;10(5):e0127149.
  • Abutaleb NS, Elhassanny AEM, Seleem MN. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb Pathog. 2022;164:105454.
  • (a) Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ. 2021;9:e11059. (b) Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN. In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother. 2021;65(4):e01715-20. (c) Kaur J, Cao X, Abutaleb NS, Elkashif A, Graboski AL, Krabill AD, AbdelKhalek AH, An W, Bhardwaj A, Seleem MN, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem. 2020;63(17):9540–9562.
  • (a) Nocentini A, Angeli A, Carta F, Winum JY, Zalubovskis R, Carradori S, Capasso C, Donald WA, Supuran CT. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580. (b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31(3):345–360. (c) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med Res Rev. 2020;40(6):2485–2565.
  • (a) Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35(1):1462–1470. (b) Supuran CT. Carbonic anhydrase inhibitors from marine natural products. Mar Drugs. 2022;20(11):721. (c) Atanasov AG, Zotchev SB, Dirsch VM. International natural product sciences taskforce, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–216.
  • (a) Angeli A, Tanini D, Nocentini A, Capperucci A, Ferraroni M, Gratteri P, Supuran CT. Selenols: a new class of carbonic anhydrase inhibitors. Chem Commun. 2019;55(5):648–651. (b) Tanini D, Capperucci A, Ferraroni M, Carta F, Angeli A, Supuran CT. Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors. Eur J Med Chem. 2020;185:111811. (c) Angeli A, Carta F, Donnini S, Capperucci A, Ferraroni M, Tanini D, Supuran CT. Selenolesterase enzyme activity of carbonic anhydrases. Chem Commun. 2020;56(32):4444–4447. (d) Angeli A, Ferraroni M, Capperucci A, Tanini D, Costantino G, Supuran CT. Selenocarbamates as a prodrug-based approach to carbonic anhydrase inhibition. ChemMedChem. 2022;17(11):e202200085.
  • Bouzina A, Berredjem M, Nocentini A, Bua S, Bouaziz Z, Jose J, Le Borgne M, Marminon C, Gratteri P, Supuran CT. Ninhydrins inhibit carbonic anhydrases directly binding to the metal ion. Eur J Med Chem. 2021;209:112875.
  • De Luca V, Giovannuzzi S, Supuran CT, Capasso C. May sulfonamide inhibitors of carbonic anhydrases from Mammaliicoccus sciuri prevent antimicrobial resistance due to gene transfer to other harmful staphylococci? Int J Mol Sci. 2022;23(22):13827.
  • Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971; 246:2561–2573.
  • (a) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem. 2007;7(9):901–908. (b) Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum JY, Scozzafava A, Supuran CT, Williams KJ. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600.
  • (a) Mori M, Supuran CT. Acipimox inhibits human carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):672–679. (b) Nishimori I, Minakuchi T, Morimoto K, Sano S, Onishi S, Takeuchi H, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem. 2006;49(6):2117–2126.
  • (a) Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett. 2010;20(15):4511–4514. (b) Gülçin İ, Scozzafava A, Supuran CT, Akıncıoğlu H, Koksal Z, Turkan F, Alwasel S. The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. J Enzyme Inhib Med Chem. 2016;31(6):1095–1101.
  • De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem. 2012;111:117–129.
  • Abbate F, Supuran CT, Scozzafava A, Orioli P, Stubbs MT, Klebe G. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J Med Chem. 2002;45(17):3583–3587.